{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Number of participants with serious adverse events","groups":[{"description":"Lenalidomide, prednisone and dexamethasone as outlined in Intervention Descriptions.\n\nLenalidomide: - Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;\n\n* Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;\n* Dose Level -4: Discontinue\n\nPrednisone: - Starting Dose: 100 mg PO days 1-5 every 28 days;\n\n* Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;\n* Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;\n* Dose level -3: Discontinue\n\nDexamethasone: - Starting Dose: 40 mg daily on days 1 - 4 every 28 days;\n\n* Dose level -1: 20 mg daily on days 1 - 4 every 28 days;\n* Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;\n* Dose level -2: 10 mg daily on days 1 - 4 every 28 days;\n* Dose level -3: Discontinue","id":"OG000","title":"Response Adapted Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 1 through Off Study Date, an average of 48 months","title":"Number of Participants With Serious Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}